Table1

Table I Patient characteristics

	No	Age (y)	sex	Location	Pathology	stage(TNM)	IRS-Group	registered clinical study group
Group non-Cx	1	0.6	M	Bladder	embryonal	2	Ⅲ	JRSG
	2	4.4	M	Prostate	embryonal	2	Ⅲ	JRSG
Group Cx	3	0.9	M	Prostate	unknown	3	Ⅲ	non
	4	2.7	F	Bladder	embryonal	3	Ⅲ	non
	5	2.8	M	Prostate	embryonal	3	Ⅲ	JRSG

Abbreviations; IRS: intergroup rhabdomyosarcoma study group, M: male, F: female, JRSG: Japan Rhabdomyosarcoma Study Group

Table2

Table II Treatment summary and patient outcome

	Pt no	Cx	PBT					Radiotherapy other than PBT	HDC ± Auto HST	Surgery	Outcome	Months to last f/u	Complications at last visit
			GyE (Fr)	Combined Cx	Lowest WBC (/uL)	BTF	Adverse event						
Group non-Cx	1	1st: VAC 2nd: VID	41.4 (23)	none	2,100	none	none	No	No	RCP + SC*	1CR	37	none
	2	1st: VAC 2nd: irinotecan 3rd: CDDP-based	41.4 (23)	none	2,400	none	Catheter related infection	Yes; X-ray 45Gy local	Yes; Tepa 960mg/m2 Mel 224 mg/m2	RCP + CUR	1CR	93	hydronephrosis**
Group Cx	3	1st: VAC	50.4 (28)	VC	500	RBC	dermatitis	No	No	Gross total resection	1CR	10	none
	4	1st: VAC 2nd: CDDP-based 3rd: irinotecan+VCR 4th: reduced VAC	45 (25)	VAC	700	none	Cystitis, vaginal fistula	No	No	RC + CUR	1CR	56	mild hydronephrosis
	5	1st: VAC 2nd: VDC/IE 3rd: back to VAC	50.4 (28)	VC	100	RBC	Local pain with phentanyl	No	No	Biopsy	VGPR ⇒SD	11	none

Abbreviations; Pt no: patients' number, BTF: Blood Transfusion, HST: hematopoietic stem cell transfusion, CR: complete response, VGPR: very good partial response, SD: stable disease, RCP: radical cystoprostatectomy, SC: sigmoid colon conduit, CUR: continent urinary reservoir, RC: radical cystectomy, Abbreviations; Pt no: patients' number, PBT: proton beam therapy, Cx: chemotherapy, WBC: white blood cell count, VAC: Consists of

Vincristine 1.5mg/m2 day 0,7,14, Actinomycine-D 0.045 mg/kg day 0 and Cyclophosphamide 2,200 mg/m2 day1, VC: Consists of Vincristine 1.5mg/m2 day 0,7,14 and Cyclophosphamide 2,200 mg/m2 day1, VID; Consists of VCR 1.0 mg/m2 + IFO 1,200 mg/m2 and DOX 25 mg/m2, VDS/IE: Consists of Vincristine 1.5 mg/m2 day0, Doxorubicin 37.5mg/m2 day0,1, Cyclophosphamide 1,200 mg/m2 day0, Ifosphamide 1,800 mg/m2 days 14 through 18 and Etoposide 100mg/m2 days14 through 18.

*Diversion to continent urinary reservoir being under consideration. **Due to ureterointestinal anastomosis stricture.